A bill for an act relating to the right to try Act.

This bill would expand access to experimental treatments for Iowa patients with terminal or life-threatening illnesses who have exhausted all FDA-approved options. It establishes a framework allowing patients to receive investigational drugs, biological products, or devices that have completed Phase 1 FDA clinical trials but remain unapproved for general use. Eligible patients must obtain physician attestation, written informed consent detailing risks and costs, and documentation of failed standard treatments, with specific requirements for both terminal illness and life-threatening conditions. The bill was introduced in March 2025 but withdrawn before committee action.